Concepedia

Publication | Open Access

Polymorphic <i>MLH1</i> and risk of cancer after methylating chemotherapy for Hodgkin lymphoma

DOIFull Paper Access

40

Citations

21

References

2007

Year

Lisa Worrillow, A. G. Smith, Kathryn Scott, Michael Andersson, A. John Ashcroft, Graça M. Dores, Bengt Glimelius, Eric J. Holowaty, Graham Jackson, Gail Jones,
Journal of Medical Genetics

Abstract

These data support the hypothesis that the common polymorphism at position -93 in the core promoter of MLH1 defines a risk allele for the development of cancer after methylating chemotherapy for Hodgkin lymphoma. However, replication of this finding in larger studies is suggested.

References

YearCitations

Page 1